<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="339">
  <stage>Registered</stage>
  <submitdate>30/08/2005</submitdate>
  <approvaldate>2/09/2005</approvaldate>
  <actrnumber>ACTRN12605000267651</actrnumber>
  <trial_identification>
    <studytitle>Essential Fatty Acid Supplementation in Psychosis</studytitle>
    <scientifictitle>A study investigating the influence of eicosapentanoic acid (EPA) supplementation in First Episode Psychotic Patients on clinical outcome and cognition</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>First episode Psychosis</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Psychosis and personality disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>2 g eicosapenaenoic acid added on to standard treatment</interventions>
    <comparator>Standed treatment</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Symptomatic improvement measured in change scores</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Symptomatic improvement measured in time to remission</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Symptomatic improvement measured in time to response</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Symptomatic improvement measured in total commulative dose</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Tolerability measures: Extra-pyramidal symptoms , niacin sensitivity as predictor for treatment response to EPA, effects of EPA on H-Magnetic Resonance spectroscpy, effects of EPA on cognition.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients meeting criteria for first episode psychosis, living in the North Western region of Melbourne, encompassing patients with DSM IV diagnosis of schizoprenia, schizoprheniform psychosis, schizoaffective disorder, Psychosis NOS.</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>29</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered containers (provided by clinical trials pharmacy of the Royal Melbourne Hospital)</concealment>
    <sequence>computer generated randomization (no stratification)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>add on to standard antipsychotic treatment</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/11/1999</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Swiss National Science Foundation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Swiss Natioanl Science Foudation</fundingname>
      <fundingaddress />
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>M&amp;W lichtenstein Foundation</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Laxdale Ltd.</fundingname>
      <fundingaddress />
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>ORYGEN Research Centre</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Laxdale Ltd</sponsorname>
      <sponsoraddress />
      <sponsorcountry>United Kingdom</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study investigates the influence of Eicosapentanoic acid (EPA) in first episode psychotic patients. The influence of EPA supplementation has been investigated only in neuroleptic-treated, mostly chronic patients with schizophrenia. The effect size of EPA supplementation in addition to antipsychotic treatment in these studies was approximately 20%. We suggest that the effect in early course of illness is even stronger and long-term consequences could be avoided. For ethical reasons at this point ALL patients get a standard treatment with an atypical antipsychotic (standard treatment for first episode patients at EPPIC) in a flexible dose regime. After inclusion into the study patients are randomised to two arms. One arm will be supplemented with a mineral oil (4 capsules of 0.5g) which is not absorbed by the gastrointestinal tract (placebo group). The other arm will be supplemented with purified Eicosapentanoic acid (4 capsules of 0.5g). Patients who give written informed consent will do standard clinical and neuropsychological tests (CANTAB) at baseline and after 12 weeks of supplementation (pre/post study design). A topical Niacin flush test (already approved by the research and ethics committee within following project: Psychobiology and Prevention of Transition to Psychosis 29/7/99) will also be applied at baseline and after 12weeks.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>North Western Mental Health Research &amp; Ethics committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gregor Berger</name>
      <address>ORYGEN Research Centre
35 Poplar Rd
Parkville VIC 3052</address>
      <phone>+61 3 93422800</phone>
      <fax>+61 3 93873003</fax>
      <email>gregor@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Gregor Berger</name>
      <address>ORYGEN Research Centre
35 Poplar Rd
Parkville VIC 3052</address>
      <phone>+61 3 93422800</phone>
      <fax>+61 3 93873003</fax>
      <email>gregor@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>